Not Medicare Enrolled

Dr. Mohammad Jahanzeb, MD

Hematology & Oncology · Boca Raton, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
2155 W MAYA PALM DR, Boca Raton, FL 33432
9104830486
In practice since 2005 (20 years)
NPI: 1114919503 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jahanzeb from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jahanzeb? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Jahanzeb

Dr. Mohammad Jahanzeb is a hematology & oncology in Boca Raton, FL, with 20 years in practice. Based on federal Medicare data, Dr. Jahanzeb performed 10,010 Medicare services across 415 unique beneficiaries.

Between the years covered by Open Payments, Dr. Jahanzeb received a total of $1,149,422 from 84 pharmaceutical and/or device companies across 1302 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Jahanzeb is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 26% volume in FL$ $1,149,422 industry payments

Medicare Practice Summary

Medicare Utilization ↗
10,010
Medicare services
Top 26% in FL for hematology & oncology
415
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~500 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Anti-nausea injection (aprepitant)4,680$1$5
Denosumab injection (Prolia/Xgeva)3,660$18$51
Dexamethasone injection (steroid)490$0$3
Anti-nausea injection (Aloxi/palonosetron)360$1$28
Complete blood count (CBC) with differential174$8$29
Blood draw (venipuncture)135$8$9
Injection of additional new drug or substance into vein100$12$61
Office visit, established patient (30-39 min)94$100$339
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less74$21$84
Administration of chemotherapy into vein, 1 hour or less72$101$378
Drug injection, under skin or into muscle67$11$69
Injection, diphenhydramine hcl, up to 50 mg30$1$3
Office visit, established patient (20-29 min)25$67$239
Infusion into a vein for hydration, each additional hour22$10$42
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less16$46$189
New patient office visit (45-59 min)11$111$453
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
94.5% medium
4.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,149,422
Total received (2018-2024)
Avg $164,203/year across 7 years
Top 1% in FL for hematology & oncology
84
Companies
1,302
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$891,587 (77.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$228,902 (19.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,683 (2.3%)
Scientific / Research
Research funding and grants
$2,250 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$316,575
2023
$220,840
2022
$250,505
2021
$111,873
2020
$85,510
2019
$85,565
2018
$78,554

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$308,383
AstraZeneca Pharmaceuticals LP
$210,597
Daiichi Sankyo Inc.
$121,945
Regeneron Healthcare Solutions, Inc.
$106,286
Merck Sharp & Dohme LLC
$68,948
Gilead Sciences, Inc.
$65,653
Merck Sharp & Dohme Corporation
$45,421
Takeda Pharmaceuticals International, Inc.
$31,553
Bard Peripheral Vascular, Inc.
$26,047
Novocure Inc.
$25,429
Novartis Pharmaceuticals Corporation
$22,859
Stemline Therapeutics Inc.
$17,882
PFIZER INC.
$17,424
Mirati Therapeutics, Inc.
$13,624
F. Hoffmann-La Roche AG
$11,352
PUMA BIOTECHNOLOGY, INC.
$8,734
Amgen Inc.
$8,627
AbbVie, Inc.
$6,100
Genentech USA, Inc.
$5,164
PFIZER INTERNATIONAL LLC
$3,147
NOVARTIS PHARMACEUTICALS CORPORATION
$2,931
GENZYME CORPORATION
$2,751
Seagen Inc.
$2,683
ABBVIE INC.
$2,250
E.R. Squibb & Sons, L.L.C.
$1,603
Bayer HealthCare Pharmaceuticals Inc.
$1,327
Puma Biotechnology, Inc.
$1,277
Immunomedics, Inc.
$1,250
Boehringer Ingelheim Pharmaceuticals, Inc.
$963
Sirtex Medical Inc
$951
Foundation Medicine, Inc.
$747
Coherus Biosciences Inc.
$618
Ipsen Bioscience Inc
$580
GlaxoSmithKline, LLC.
$343
AtriCure, Inc.
$287
Janssen Biotech, Inc.
$252
EMD Serono, Inc.
$244
Clovis Oncology, Inc.
$204
Pharmacyclics LLC, An AbbVie Company
$202
Lilly USA, LLC
$200
Celgene Corporation
$188
ATRICURE, INC.
$161
Heron Therapeutics, Inc.
$155
Incyte Corporation
$135
Roche Diagnostics Corporation
$132
Taiho Oncology, Inc.
$128
Exelixis Inc.
$125
JAZZ PHARMACEUTICALS INC.
$124
ARRAY BIOPHARMA INC
$122
TESARO, Inc.
$119
Blueprint Medicines Corporation
$92
Astellas Pharma US Inc
$77
Pharmacyclics LLC, an AbbVie Company
$74
Eisai Inc.
$72
BARD PERIPHERAL VASCULAR, INC.
$71
Kite Pharma, Inc.
$68
Ipsen Biopharmaceuticals, Inc
$54
TerSera Therapeutics LLC
$51
Deciphera Pharmaceuticals Inc.
$46
SERVIER PHARMACEUTICALS LLC
$42
Teva Pharmaceuticals USA, Inc.
$39
Medtronic, Inc.
$37
Octapharma USA, Inc.
$37
Mylan Institutional Inc.
$36
Advanced Accelerator Applications
$32
Seattle Genetics, Inc.
$29
EISAI INC.
$25
Blue Earth Diagnostics Limited
$24
PharmaEssentia USA Corporation
$24
Servier Pharmaceuticals LLC
$24
Emmaus Medical, Inc.
$22
Array BioPharma Inc.
$21
Kyowa Kirin, Inc.
$21
TOLMAR Pharmaceuticals, Inc.
$20
Partner Therapeutics, Inc.
$20
Jazz Pharmaceuticals Inc.
$19
G1 Therapeutics, Inc.
$19
Sun Pharmaceutical Industries Inc.
$18
Dova Pharmaceuticals
$17
GE HEALTHCARE
$15
Fortovia Therapeutics, Inc.
$15
Organon LLC
$13
MACROGENICS, INC.
$12
Secura Bio, Inc.
$11
Top 3 companies account for 55.8% of total payments
Associated products mentioned in payments ›
6 · ADCETRIS · ALIMTA · ALUNBRIG · ATACAND · ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) · Abraxane · Alecensa · Aliqopa · Avastin · Axumin · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · ENHERTU · ERBITUX · EXKIVITY · Endari · Enhertu · FOUNDATIONONE · FOUNDATIONONE CDX · FOUNDATIONONE LIQUID · Farydak · Fulphila · GAVRETO · GILOTRIF · Halaven · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LEUKINE · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lutathera · MARGENZA · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Non-Covered · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONTRUZANT · OPDIVO · OPTUNE LUA (NOVOTTF-200T) · OSTEOCOOL RF ABLATION SYSTEM · Optune · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · Padcev · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rubraca · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUSTOL · Stivarga · TABRECTA · TAGRISSO · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tibsovo · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VONVENDI · Vectibix · Venclexta · XALKORI · XGEVA · XTANDI · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (78%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in FL.

Equivalent to $11,483 per 100 Medicare services performed
Looking for a hematology & oncology in Boca Raton?
Compare hematology & oncologys in the Boca Raton area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
78
Per 100K population
5.2
County median income
$81,115
Nearest hospital
BOCA RATON REGIONAL HOSPITAL
2.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Jahanzeb is a mixed practice specialist, with above-average Medicare volume (top 26% in FL), and high industry engagement (speaking/promotional, top 1%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Jahanzeb experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Jahanzeb performed 4,680 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jahanzeb receive payments from pharmaceutical companies?
Yes. Dr. Jahanzeb received a total of $1,149,422 from 84 companies across 1,302 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jahanzeb's costs compare to other hematology & oncologys in Boca Raton?
Dr. Jahanzeb's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jahanzeb) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →